Comparison of muscle relaxant dose of cis-atracurium based on body fat mass (FFM), total body weight (TBW) and ideal body weight (IBW) in patients undergoing obesity surgery.

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20151107024909N9

Enrollment

Registered

2020-03-11

Start date

2020-01-29

Completion date

Unknown

Last updated

2020-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity. Overweight and obesity

Interventions

Intervention 1: Intervention group1:In the first group, the dose of cis atracurium was injected based on body fat mass (FFM) and changed during the dose of the drug based on the patient's hemodynamic

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Ages 18 to 60 Patients with physical level below 3 according to the American Society of Anesthesiologists classification BMI greater than ²35 kg / m Normal kidney and liver function confirmed by routine screening tests

Exclusion criteria

Exclusion criteria: Pregnancy , Neuromuscular Disease Treatment with Well-known Interventions in Muscle Neurotransmission Psychological Disorder Allergy to Cis-atracurium Criteria for Difficult Intubation

Design outcomes

Primary

Measure	Time frame
Duration of muscle relaxation. Timepoint: During surgery. Method of measurement: Minutes.;Dose of Cisatracurium. Timepoint: During surgery. Method of measurement: Mg, syringe.	—

Secondary

Measure	Time frame
Need for antagonism. Timepoint: During surgery and after surgery. Method of measurement: Mg, syringe.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFaranak Rokhtabnak

Iran University of Medical Sciences

rolhtabnak.f@iums.ac.ir+98 21 8871 7272

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 8, 2026